Anti-KI21A/ KIF21A/ CFEOM1 monoclonal antibody

Anti-KI21A/ KIF21A/ CFEOM1 antibody for FACS & in-vivo assay

Target products collectionGo to KIF21A/KIF21A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2174-Ab-1/ GM-Tg-hg-MP2174-Ab-2Anti-Human KIF21A monoclonal antibodyHuman
GM-Tg-rg-MP2174-Ab-1/ GM-Tg-rg-MP2174-Ab-2Anti-Rat KIF21A monoclonal antibodyRat
GM-Tg-mg-MP2174-Ab-1/ GM-Tg-mg-MP2174-Ab-2Anti-Mouse KIF21A monoclonal antibodyMouse
GM-Tg-cynog-MP2174-Ab-1/ GM-Tg-cynog-MP2174-Ab-2Anti-Cynomolgus/ Rhesus macaque KIF21A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2174-Ab-1/ GM-Tg-felg-MP2174-Ab-2Anti-Feline KIF21A monoclonal antibodyFeline
GM-Tg-cang-MP2174-Ab-1/ GM-Tg-cang-MP2174-Ab-2Anti-Canine KIF21A monoclonal antibodyCanine
GM-Tg-bovg-MP2174-Ab-1/ GM-Tg-bovg-MP2174-Ab-2Anti-Bovine KIF21A monoclonal antibodyBovine
GM-Tg-equg-MP2174-Ab-1/ GM-Tg-equg-MP2174-Ab-2Anti-Equine KIF21A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2174-Ab-1/ GM-Tg-hg-MP2174-Ab-2; GM-Tg-rg-MP2174-Ab-1/ GM-Tg-rg-MP2174-Ab-2;
GM-Tg-mg-MP2174-Ab-1/ GM-Tg-mg-MP2174-Ab-2; GM-Tg-cynog-MP2174-Ab-1/ GM-Tg-cynog-MP2174-Ab-2;
GM-Tg-felg-MP2174-Ab-1/ GM-Tg-felg-MP2174-Ab-2; GM-Tg-cang-MP2174-Ab-1/ GM-Tg-cang-MP2174-Ab-2;
GM-Tg-bovg-MP2174-Ab-1/ GM-Tg-bovg-MP2174-Ab-2; GM-Tg-equg-MP2174-Ab-1/ GM-Tg-equg-MP2174-Ab-2
Products NameAnti-KIF21A monoclonal antibody
Formatmab
Target NameKIF21A
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KIF21A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species KI21A/ KIF21A/ CFEOM1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2174
    Target NameKIF21A
    Gene ID55605,16564,300158,699150,100683402,101095182,540076,100070369
    Gene Symbol and SynonymsCFEOM1,FEOM1,FEOM3A,KIF21A
    Uniprot AccessionQ7Z4S6
    Uniprot Entry NameKI21A_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000139116
    Target ClassificationN/A

    The target: KIF21A, gene name: KIF21A, also named as CFEOM1, FEOM1, FEOM3A. This gene encodes a member of the KIF4 subfamily of kinesin-like motor proteins. The encoded protein is characterized by an N-terminal motor domain a coiled-coil stalk domain and a C-terminal WD-40 repeat domain. This protein may be involved in microtubule dependent transport. Mutations in this gene are the cause of congenital fibrosis of extraocular muscles-1. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Mar 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.